Caisse DE Depot ET Placement DU Quebec lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,125 shares of the biotechnology company’s stock after selling 400 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in United Therapeutics were worth $2,090,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its stake in shares of United Therapeutics by 4.2% in the 3rd quarter. SG Americas Securities LLC now owns 10,799 shares of the biotechnology company’s stock valued at $1,266,000 after purchasing an additional 436 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 6.9% in the 3rd quarter. Pacer Advisors Inc. now owns 7,188 shares of the biotechnology company’s stock valued at $842,000 after purchasing an additional 461 shares during the last quarter. ETRADE Capital Management LLC grew its stake in shares of United Therapeutics by 18.8% in the 4th quarter. ETRADE Capital Management LLC now owns 2,937 shares of the biotechnology company’s stock valued at $435,000 after purchasing an additional 465 shares during the last quarter. Amalgamated Bank grew its stake in shares of United Therapeutics by 6.0% in the 4th quarter. Amalgamated Bank now owns 8,685 shares of the biotechnology company’s stock valued at $1,285,000 after purchasing an additional 489 shares during the last quarter. Finally, American International Group Inc. grew its stake in shares of United Therapeutics by 0.6% in the 4th quarter. American International Group Inc. now owns 91,580 shares of the biotechnology company’s stock valued at $13,549,000 after purchasing an additional 524 shares during the last quarter.

How to Become a New Pot Stock Millionaire

Shares of United Therapeutics Co. (NASDAQ:UTHR) opened at $111.88 on Thursday. The company has a quick ratio of 3.01, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $4,830.00, a P/E ratio of 10.22 and a beta of 1.32. United Therapeutics Co. has a 1-year low of $107.82 and a 1-year high of $152.55.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 EPS for the quarter, beating the consensus estimate of $3.59 by $0.30. The business had revenue of $464.70 million during the quarter, compared to analysts’ expectations of $420.55 million. United Therapeutics had a return on equity of 17.15% and a net margin of 19.37%. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the firm earned $4.12 EPS. sell-side analysts anticipate that United Therapeutics Co. will post 12.46 earnings per share for the current fiscal year.

Several brokerages have weighed in on UTHR. ValuEngine downgraded United Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. BidaskClub downgraded United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 24th. Barclays reiterated an “underweight” rating and issued a $105.00 target price (down from $115.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Credit Suisse Group reiterated an “underperform” rating and issued a $115.00 target price (down from $120.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 target price on the stock in a research note on Monday, January 15th. Five analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $135.20.

In other news, CEO Martine A. Rothblatt sold 21,512 shares of the firm’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $112.55, for a total value of $2,421,175.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.80% of the stock is owned by company insiders.

WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/15/caisse-de-depot-et-placement-du-quebec-reduces-position-in-united-therapeutics-co-uthr.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.